FORM 3

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

OMB APPROVAL						
OMB Number:		3235- 0104				
Estimated average burden						
hours por	er e:	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

**SECURITIES** 

Name and Address of Reporting Person     Cobb Stuart	Requiring (Month/Da	2. Date of Event Requiring Statement (Month/Day/Year) 12/18/2023  3. Issuer Name and Ticker or Trading Symbol Neurogene Inc. [ NGNE ]							
(Last) (First) (Middle) C/O NEUROGENE INC.			4. Relationship of Reporting Issuer (Check all applicable)	Person(s) to		5. If Amendment, Date of Original Filed (Month/Day/Year)			
535 W 24TH STREET, 5TH FLOC	OR		Director  X Officer (give title below)		specify	6. Individual or Jo (Check Applicable			
(Street) NEW YORK NY 10011			Chief Scientific	,		A Person	by One Reporting by More than One Person		
(City) (State) (Zip)									
Table I - Non-Derivative Securities Beneficially Owned									
, ,		2. Amount of Securities Beneficially Owned (Instr. 4)	3. Owner Form: D (D) or Ir (I) (Instr	Direct C	. Nature of Indire Iwnership (Instr.	lature of Indirect Beneficial nership (Instr. 5)			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable Expiration Date (Month/Day/Year)		ate	(Instr. 4) or Exer		Conversi or Exerci	ise Form:	6. Nature of Indirect Beneficial Ownership (Instr.		
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivativ Security	Direct (D) or Indirect (I) (Instr. 5)	5)		
Stock Option (Right to Buy)	(1)	10/15/2030	Common Stock	22,680	10.71	D			
Stock Option (Right to Buy)	(2)	09/22/2031	Common Stock	15,352	23.02	D			
Stock Option (Right to Buy)	(3)	03/08/2033	Common Stock	22,680	18.39	D			
Stock Option (Right to Buy)	(4)	03/10/2029	Common Stock	13,514	5.82	D			

#### Explanation of Responses:

- 1. This option represents a right to purchase 22,680 shares of the Issuer's common stock. 25% of this option vested on October 7, 2021, with the remainder vesting in equal monthly installments through October 7, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- 2. This option represents a right to purchase 15,352 shares of the Issuer's common stock. 25% of this option vested on September 23, 2022, with the remainder vesting in equal monthly installments through September 23, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- 3. This option represents a right to purchase 22,680 shares of the Issuer's common stock. 25% of this option will vest on March 9, 2024, with the remainder vesting in equal monthly installments through March 9, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- 4. This option represents a right to purchase 13,514 shares of the Issuer's common stock and is fully vested.

### Remarks:

Exhibit 24 - Power of Attorney

/s/ Christine Mikail, as attorney-in-fact for Stuart 12/26/2023 Cobb

\*\* Signature of Reporting Date

Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of Rachel McMinn, Christine Mikail, Ryan A. Murr and Branden C. Berns, and any of their substitutes, signing singly, as the undersigned's true and lawful attorney-in-fact to:

- 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other document necessary or appropriate to obtain codes, passwords, and passphrases enabling the undersigned to make electronic filings with the SEC of reports require by the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- 2. execute for and on behalf of the undersigned, in the undersigned's capacity as a director, officer and/or ten percent stockholder of Neurogene Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any securities exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned also ratifies hereby any action previously taken by each attorney-in-fact that would have been authorized by this power of attorney if it has been in effect at the time such action was taken. The undersigned acknowledges that each attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September 18, 2023.

By: /s/ Stuart Cobb

Name: Stuart Cobb